Trinity Biotech buys Bartels for $9.3 million:
This article was originally published in Clinica
Executive Summary
Trinity Biotech has bought the assets and goodwill of Intracel division Bartels, a manufacturer of cell dependent infectious agent diagnostics, for $9.3 million in stock and cash. The product range includes antigen detection kits for herpes simplex virus, as well as respiratory viruses, including A and B types flu, para-influenza viruses 1, 2 and 3 and respiratory syncitial virus. It also manufactures and sells infectious disease confirmatory reagents. Dublin, Ireland-based Trinity Biotech says the acquisition of Bartels, based in Issaquah, Washington, will strengthen its distribution capabilities in the US.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.